Zhou X, Garbinsky D, Ouyang J, Davenport E, Agarwal I, Oberdhan D. Longitudinal data on treatment duration and compliance from autosomal dominant polycystic kidney disease clinical trials with tolvaptan. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa139.S. doi: 10.1093/ndt/gfaa139.SO093
Zhou X, Davenport E, Ouyang J, Hoke M, Garbinsky D, Agarwal I, Oberdhan D. Population characteristics across an expanded pooled database of multiple autosomal dominant polycystic kidney disease clinical studies. Nephrol Dial Transplant. 2020 Jun;35(Supplement_3):gfaa142.P. doi: 10.1093/ndt/gfaa142.P0037
Lucas AM, Armbruster B. The cost-effectiveness of expanded HIV screening in the United States. AIDS. 2013 Mar 13;27(5):795-801. doi: 10.1097/QAD.0b013e32835c54f9
Mauskopf J, Brogan AJ, Talbird SE, Martin S. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS. 2012 Jan 1;26(3):355-64.
Pipkin S, Scheer S, Okeigwe I, Schwarcz S, Harris DH, Hessol NA. The effect of HAART and calendar period on Kaposi's sarcoma and non-Hodgkin lymphoma: results of a match between an AIDS and cancer registry. AIDS. 2011 Feb 20;25(4):463-71.
Doward LC, Dietz B, Wilburn J, McKenna SP, Bhor M, Rajagopalan R. Impact of lipoatrophy on patient-reported outcomes in ART-experienced patients. AIDS. 2008 May 1;20(10):1197-201.
Steenbergen C, Afshari CA, Petranka JG, Collins J, Martin K, Bennett L, Haugen A, Bushel P, Murphy E. Alterations in apoptotic signaling in human idiopathic cardiomyopathic hearts in failure. Am J Physiol Heart Circ Physiol. 2003 Jan 1;284(1):H268-76.